Document is current
Any future updates will be listed below
-
Authors
Sugita, Mayumi
Wilkes, David C. https://orcid.org/0000-0002-2422-1145
Bareja, Rohan
Eng, Kenneth W.
Nataraj, Sarah
Jimenez-Flores, Reyna A.
Yan, LunBiao
De Leon, Jeanne Pauline
Croyle, Jaclyn A.
Kaner, Justin
Merugu, Swathi
Sharma, Sahil
MacDonald, Theresa Y.
Noorzad, Zohal
Panchal, Palak
Pancirer, Danielle
Cheng, Shuhua
Xiang, Jenny Z.
Olson, Luke
Van Besien, Koen
Rickman, David S. https://orcid.org/0000-0001-7420-5883
Mathew, Susan
Tam, Wayne https://orcid.org/0000-0003-4283-0005
Rubin, Mark A. https://orcid.org/0000-0002-8321-9950
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
Sboner, Andrea
Hassane, Duane C.
Chiosis, Gabriela https://orcid.org/0000-0003-0486-6920
Elemento, Olivier
Roboz, Gail J.
Mosquera, Juan Miguel https://orcid.org/0000-0003-4666-6476
Guzman, Monica L. https://orcid.org/0000-0002-9262-8246
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA234478-01)
Hirschl/Weill-Caulier Research Award (no number).
- License Information
-
More Information
Article History
Received: 26 June 2020
Accepted: 18 February 2021
First Online: 26 May 2021
Competing interests
: Memorial Sloan-Kettering Cancer Center holds the intellectual rights to PU-H71. Samus Therapeutics, of which Dr. Chiosis has partial ownership, has licensed PU-H71. D.C.H. receives research funding from Daiichi Sankyo. O.E. is a co-founder and equity holder for Volastra Therapeutics and OneThree Biotech, and is a SAB member and equity holder for Owkin, Freenome, Genetic Intelligence, and Acuamark DX. O.E. receives funding from Eli Lilly, Janssen, and Sanofi. G.J.R. serves as a consultant to Abbvie, Actinium, Agios, Amphivena, Argenx, Array Biopharma, Astex, Astellas, AstraZeneca, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jasper Therapeutics, Jazz, MEI Pharma–IDMC Chair, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda-IRC chair, Trovagene. M.S., D.C.H., G.J.R., and M.L.G. receive research funding from Cellectis. M.L.G. serves as a consultant SeqRx. G.C. and M.L.G. have patents, royalties and intellectual rights to the PU-FITC assay. The other co-authors declare that they have no competing interests.
